Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review
Primary pulmonary choriocarcinoma (PPC) is an extremely rare malignant cancer in men with no clinical guidelines for the treatment. Cytotoxic chemotherapy has a limited effect on the prognosis of PPC. Recently, immune checkpoint inhibitors (ICIs) have shown promising treatment effectiveness. A liter...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1523316/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590850376335360 |
|---|---|
| author | Xiaojing Liang Guoqing Xu Jisong Zhang Li Xu Liangliang Dong Xiaoyue Wang Weidong Han Enguo Chen |
| author_facet | Xiaojing Liang Guoqing Xu Jisong Zhang Li Xu Liangliang Dong Xiaoyue Wang Weidong Han Enguo Chen |
| author_sort | Xiaojing Liang |
| collection | DOAJ |
| description | Primary pulmonary choriocarcinoma (PPC) is an extremely rare malignant cancer in men with no clinical guidelines for the treatment. Cytotoxic chemotherapy has a limited effect on the prognosis of PPC. Recently, immune checkpoint inhibitors (ICIs) have shown promising treatment effectiveness. A literature review revealed that a combination of chemotherapy and ICIs could prolong the survival time of PPC patients. Herein, we report a 67-year-old man with a cough, expectoration, and blood in the sputum, presenting with a mass in the lower lobe of the right lung. The hematoxylin and eosin staining and immunohistochemical profile of the primary lesion showed features of choriocarcinoma, accompanied by elevations in serum human chorionic gonadotropin (HCG) levels. Programmed death-ligand 1 (PD-L1) expression was positive (70%) in the 22C3 assay. He received a combination of cisplatin, etoposide, paclitaxel, and sintilimab. Four months after the treatment began, chest computed tomography (CT) showed significant mass reduction. Therefore, ICIs may be a promising therapy option for patients with PPC. |
| format | Article |
| id | doaj-art-e075df7cc461436baed5304c787dfc87 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-e075df7cc461436baed5304c787dfc872025-01-23T06:56:41ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011610.3389/fimmu.2025.15233161523316Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature reviewXiaojing Liang0Guoqing Xu1Jisong Zhang2Li Xu3Liangliang Dong4Xiaoyue Wang5Weidong Han6Enguo Chen7Department of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Pulmonary and Critical Care Medicine, National Regional Medical Center, Zhejiang University Sir Run Run Shaw Alaer Hospital, Alaer, Xinjiang, ChinaDepartment of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Medical Oncology, the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, ChinaDepartment of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, ChinaPrimary pulmonary choriocarcinoma (PPC) is an extremely rare malignant cancer in men with no clinical guidelines for the treatment. Cytotoxic chemotherapy has a limited effect on the prognosis of PPC. Recently, immune checkpoint inhibitors (ICIs) have shown promising treatment effectiveness. A literature review revealed that a combination of chemotherapy and ICIs could prolong the survival time of PPC patients. Herein, we report a 67-year-old man with a cough, expectoration, and blood in the sputum, presenting with a mass in the lower lobe of the right lung. The hematoxylin and eosin staining and immunohistochemical profile of the primary lesion showed features of choriocarcinoma, accompanied by elevations in serum human chorionic gonadotropin (HCG) levels. Programmed death-ligand 1 (PD-L1) expression was positive (70%) in the 22C3 assay. He received a combination of cisplatin, etoposide, paclitaxel, and sintilimab. Four months after the treatment began, chest computed tomography (CT) showed significant mass reduction. Therefore, ICIs may be a promising therapy option for patients with PPC.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1523316/fullprimary pulmonary choriocarcinomachemotherapyimmune checkpoint inhibitorsprogrammed death-ligand 1human chorionic gonadotropin |
| spellingShingle | Xiaojing Liang Guoqing Xu Jisong Zhang Li Xu Liangliang Dong Xiaoyue Wang Weidong Han Enguo Chen Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review Frontiers in Immunology primary pulmonary choriocarcinoma chemotherapy immune checkpoint inhibitors programmed death-ligand 1 human chorionic gonadotropin |
| title | Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review |
| title_full | Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review |
| title_fullStr | Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review |
| title_full_unstemmed | Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review |
| title_short | Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review |
| title_sort | combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma a case report and literature review |
| topic | primary pulmonary choriocarcinoma chemotherapy immune checkpoint inhibitors programmed death-ligand 1 human chorionic gonadotropin |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1523316/full |
| work_keys_str_mv | AT xiaojingliang combinationchemotherapywithsintilimabfortreatmentofamalepatientwithprimarypulmonarychoriocarcinomaacasereportandliteraturereview AT guoqingxu combinationchemotherapywithsintilimabfortreatmentofamalepatientwithprimarypulmonarychoriocarcinomaacasereportandliteraturereview AT jisongzhang combinationchemotherapywithsintilimabfortreatmentofamalepatientwithprimarypulmonarychoriocarcinomaacasereportandliteraturereview AT lixu combinationchemotherapywithsintilimabfortreatmentofamalepatientwithprimarypulmonarychoriocarcinomaacasereportandliteraturereview AT liangliangdong combinationchemotherapywithsintilimabfortreatmentofamalepatientwithprimarypulmonarychoriocarcinomaacasereportandliteraturereview AT xiaoyuewang combinationchemotherapywithsintilimabfortreatmentofamalepatientwithprimarypulmonarychoriocarcinomaacasereportandliteraturereview AT weidonghan combinationchemotherapywithsintilimabfortreatmentofamalepatientwithprimarypulmonarychoriocarcinomaacasereportandliteraturereview AT enguochen combinationchemotherapywithsintilimabfortreatmentofamalepatientwithprimarypulmonarychoriocarcinomaacasereportandliteraturereview |